Successful Phase 1A Completion in Brain Cancer CAR T Trial

Chimeric Therapeutics (ASX: CHM) has successfully treated the third participant, concluding the final dose escalation cohort in the CHM 1101 Phase 1A clinical trial at City of Hope. This phase aimed to assess the safety and maximum tolerated dose of CHM 1101 (CLTX CAR T) in patients with recurrent or progressive glioblastoma (GBM).

The trial's fourth dose cohort received a total of 440 million CHM 1101 CAR T cells through intratumoral and intraventricular routes. Safety and efficacy evaluations are expected by the end of 2023. A Phase 1B trial is ongoing at the Sarah Cannon Transplant & Cellular Therapy Program, and both phases will define the recommended Phase 2 dose and schedule. Chimeric aims to advance its CHM 1101 development to further trials based on clinical data.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com